Tetraphase Pharmaceuticals, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) (NASDAQ:TTPH) securities (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018.
The complaint alleges that (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints ; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary endpoints; and (3) consequently, Defendants’ statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
“Tetraphase Pharmaceuticals, Inc.”
If you suffered a loss in Tetraphase you have until September 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.